Source-grounded facts extracted from PTC THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PTC THERAPEUTICS, INC. shareholders approved Non-binding advisory proposal on named executive officer compensation at the 2026-06-02 meeting.
“The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders with 71,166,204 votes “For,” 1,492,801 votes “Against,” 24,290 votes “Abstained,” and 3,858,311 broker non-votes.”
PTC THERAPEUTICS, INC. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.
“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s stockholders with 76,170,292 votes “For,” 355,794 votes “Against,” and 15,520 votes “Abstained.””
PTC THERAPEUTICS, INC. shareholders approved Election of four Class I directors at the 2026-06-02 meeting.
“The Company held its Annual Meeting on June 2, 2026 (the “Annual Meeting”). The results for the votes regarding each proposal at the Annual Meeting are set forth below.”
PTC THERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: revenue $273 million, net income Net loss was $2.8 million for the first quarter of 2026. Guidance raised.
“PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results – First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise”
PTC THERAPEUTICS, INC. amended Amendment No. 2 to Amended and Restated Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at $240.0 million in upfront cash consideration (effective 2025-12-29).
“On December 29, 2025, PTC Therapeutics, Inc. (the “Company”), Royalty Pharma Investments 2019 ICAV (“RPI”), and, for the limited purposes set forth in the Purchase Agreement (as defined below), Royalty Pharma plc, entered into an Amendment No. 2 to Amended and Restated Royalty Purchase Agreement (the “Amendment”), which amends that certain Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023, as amended by Amendment No. 1 dated June 17, 2024 (the “Purchase Agreement”).”
PTC THERAPEUTICS, INC. reported the first quarter ending March 31, 2024 results: revenue $210.1 million, net income $91.6 million. Guidance reaffirmed.
“many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin." Key Corporate Updates: ● First quarter 2024 total revenue of $210 million ● First quarter 2024 revenue for the DMD franchise was $161 million o TranslarnaTM (ataluren) net product revenue was $104 million, driven by new patients in existing geographies”
PTC THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $307.1 million for the fourth quarter of 2023... Total revenue was $937.8 million for full year 2023.
“PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.